Pfizer Inc PFE

Alternate Symbol(s): N.PFE

Healthcare

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

NYSE:PFE - Post by User

Pfizer Inc

<< Previous

Bullboard Posts

Next >>

Post by Humaniston Dec 22, 2020 9:02pm

79 Views

Post# 32166692

PFE near deal/POSSIBLY TMRW with us gov up to 100 mlns doses

Pfizer nears deal to provide U.S. with more vaccine doses - NYT

Dec. 22, 2020 6:57 PM ETPfizer Inc. (PFE)By: Carl Surran, SA News Editor38 Comments

Pfizer (NYSE:PFE) is close to an agreement with the Trump administration in which the company would bolster the supply of its coronavirus vaccine for the U.S. by at least tens of millions of doses next year in exchange for a government directive giving it better access to manufacturing supplies, New York Times reports.
A deal, which could be announced as early as tomorrow, would help the U.S. at least partly offset a potential vaccine shortage that could leave as many as 110M adult Americans uncovered in H1 2021.
The government is asking for 100M additional doses from Pfizer from April through June; the company has indicated it should be able to produce at least 70M doses and possibly more if it can gain more access to supplies and materials.
Pfizer and partner BioNTech (NASDAQ:BNTX) as well as rival Moderna are the only two groups that have won U.S. emergency use authorization for their respective COVID-19 vaccine candidates.